Whereas the clinical significance of BRAF mutations has been demonstrated in various disease settings, it is unclear what proportion of the MAPK alterations found in prostate cancer lead to meaningful activation of the MAPK pathway. This evidence concerns the gene BRAF and prostate cancer.